

# SCIENTIFIC PROGRAMM

### FRIDAY, NOVEMBER 24

#### JOINT SESSION I

#### Welcome & Introduction

Welcome

13:00 - 14:10

14:10 - 16:00

Christoph Zielinski

- Quality of life witrh breast cancer
- 11:00 12:10 Vesna Bjelic-Radisic Highlights of the year
  - Cornelia Kohlberg-Liedtke

Lunch Break (12:10 - 13:00)

#### **PHYSICIANS' TRACK NURSES & ADVOCACY TRACK** What I need to know in... Welcome & Introduction Introduction round (13:00 - 13:15) Symptom Management & Patient Empowerment **Breast Surgery** Advances in Breast Cancer Therapies and Symptom Peter Dubsky Management: Exploring the Latest Approaches Dr Georg Jeryczynski Radiotherapy The Effect of Chemotherapy Education Given by Tell Daniela Kauer-Dorner 13:15 - 14:00 What You've Learned Method on Management of Symptoms and Quality of Life Systemic Therapy Belkıs Güllü Gücüyener Cornelia Kohlberg-Liedtke Investigation of the Effect of Information on the Panel Discussion & Q&A Empowerment of Cancer Patients Using Question **Prompt List** Asuman Kuşçu **High Risk Breast Cancer Comprehensive Insights into Breast Cancer** TNBC: Standards in the (neo)adjuvant Setting Christian Singer Through the Lens of Courage: A Patient's Perspective Integrating novel agents in metastatic TNBC on Breast Cancer Marija Balic Karoline Eadie Escalation and De-escalation: (neo)adjuvant treatment 14:00-16:00 Advancing Public Health Initiatives in Breast Cancer: of HER2-positive disease Empowering Awareness, Early Detection, and Access to Gabriel Rinnerthaler Care The changing treatment landscape in metastatic HER2-Hans Peter Köllner positive BC Rehabilitation and Empowerment: Enhancing Quality of Kathrin Strasser-Weippl Life in Breast Cancer Survivors Management of IO Toxicity Manfred Webersberger Thorsten Fuereder

Panel Discussion & Q&A

Coffee Break (16:00 - 16:30)

**SPONSORED SESSION I** (16:30-17:30) details to be found on page 3

Coffee Break (17:30 - 17:45)

SPONSORED SESSION II (17:45-18:15) details to be found on page 3

Networking dinner (19:00)



# SCIENTIFIC PROGRAMME as by October 30, 2023

Claudia Altmann-Posposchek & Martina Spalt

SATURDAY, NOVEMBER 25 **PHYSICIANS' TRACK NURSES & ADVOCACY TRACK** Challenges in Luminal Disease Integration of CDKi and PARPi in eBC Diana Lüftner 08:30 - 09:40 Endocrine responsiveness and deescalation strategies in eBC Maximilian Marhold Sequencing treatment lines in luminal mBC Rupert Bartsch Panel Discussion & O&A WORKSHOP - Navigating Conversations: Effective The Young and the Elderly Communication in a Breast Cancer Journey Doris Christiane Schmitt (08:30 - 10:00) Optimizing adjuvant therapy in young women Addressing Side Effects and Pain Management Rupert Bartsch in Breast Cancer 09:40 - 11:00 Fertility preservation Matteo Lambertini The Breast Care Nurse: Navigating Side Effects in Breast 10:00 - 11:00 Risk adapted adjuvant therapy in the elderly Cancer Georg Pfeiler Elisabeth Wiedermann Panel Discussion & Q&A Oncologic Pain Management in a Nutshell Christopher Gonano Coffee Break (11:00 - 11:30) **Clinical Nurse Specialist -Special Clinical Considerations Findings & Experiences from the Field** Hereditary Breast Cancer and BRCA Testing Clinical nurse specialist - Findings & Experiences from 11:30-12:20 11:30 - 12:30 Christian Singer the Field Julio de la Torre Managing Brain Metastases and LMD Diana Lüftner Wrap Up

Panel Discussion & Q&A

#### JOINT SESSION II

#### Closure & Summary

Summary from each Track & Closing Remarks Christoph Zielinski & Rupert Bartsch

12:30 - 13:10



# SPONSORED PROGRAMME

## FRIDAY, NOVEMBER 24

#### **Genetic Consenting**

Welcome & Introduction *Christian Singer* 

Introduction to genetic consenting

Christian Singer Case study: Alte Christine Deutsc

17:45 - 18:15

Case study: Alternatives to genetic consenting *Christine Deutschmann* Panel Discussion & Q&A

Summary & Close

#### **Biomarkers in luminal Breast Cancer**

How do these biomarkers change the current and future treatment landscape? *Rupert Bartsch, Medical University Vienna* 

What are opportunities and challenges for implementation? *Leonhard Müllauer, Medical University Vienna* 

## **Stemline**<sup>®</sup> A Menarini Group Company

MSD AstraZeneca

### FINANCIAL SUPPORT & SPONSORS (AS BY OCT 30, 2023)

This activity is supported by educational grants from the following companies:







We kindly thank the following sponsors for their support of the 3rd CECOG Breast Cancer Academy:







**ÖSeagen**<sup>®</sup>



Stemline® A Menarini Group Company